Supplementary Table 6.
Sensitivity analysis of office DBP at 6 months
| Clinical trials | Number of patients (R/C) | Pooled effect size in mmHg (95% CI) | I2 (%) | Phet | Pz |
|---|---|---|---|---|---|
| All trials pooled | 544/371 | −2.63 (−6.70, 1.44) | 80 | <0.0001 | 0.21 |
| Excluded trial | |||||
| DENERHTN | 496/318 | −2.34 (−7.35, 2.66) | 83 | <0.0001 | 0.36 |
| DENERVHTA | 533/358 | −3.46 (−7.67, 0.74) | 81 | <0.0001 | 0.11 |
| OSLO | 535/361 | −3.72 (−7.75, 0.32) | 79 | 0.0002 | 0.07 |
| Prague-15 | 492/317 | −2.99 (−7.73, 1.74) | 82 | <0.0001 | 0.22 |
| SYMPLICITY HTN-2 | 495/320 | −1.37 (−4.21, 1.47) | 46 | 0.1 | 0.35 |
| SYMPLICITY HTN-3 | 191/200 | −2.45 (−7.87, 2.98) | 82 | <0.0001 | 0.38 |
| SYMPLICITY HTN-Japan | 522/352 | −1.87 (−6.44, 2.70) | 82 | <0.0001 | 0.42 |
DBP: Diastolic blood pressure; CI: Confidence interval; C: Control group; Phet: Significance for the heterogeneity test; Pz: Significance for the pooled effect size; R: Renal denervation group.